Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jan;28(1):63-70.
doi: 10.1038/nbt.1598. Epub 2009 Dec 27.

Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety

Alex B Burgin  1 , Olafur T Magnusson, Jasbir Singh, Pam Witte, Bart L Staker, Jon M Bjornsson, Margret Thorsteinsdottir, Sigrun Hrafnsdottir, Timothy Hagen, Alex S Kiselyov, Lance J Stewart, Mark E Gurney
Affiliations

Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety

Alex B Burgin et al. Nat Biotechnol. 2010 Jan.

Abstract

Phosphodiesterase 4 (PDE4), the primary cAMP-hydrolyzing enzyme in cells, is a promising drug target for a wide range of conditions. Here we present seven co-crystal structures of PDE4 and bound inhibitors that show the regulatory domain closed across the active site, thereby revealing the structural basis of PDE4 regulation. This structural insight, together with supporting mutagenesis and kinetic studies, allowed us to design small-molecule allosteric modulators of PDE4D that do not completely inhibit enzymatic activity (I(max) approximately 80-90%). These allosteric modulators have reduced potential to cause emesis, a dose-limiting side effect of existing active site-directed PDE4 inhibitors, while maintaining biological activity in cellular and in vivo models. Our results may facilitate the design of CNS therapeutics modulating cAMP signaling for the treatment of Alzheimer's disease, Huntington's disease, schizophrenia and depression, where brain distribution is desired for therapeutic benefit.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. J Pharmacol Exp Ther. 2007 Nov;323(2):708-19 - PubMed
    1. J Pharmacol Exp Ther. 2001 Sep;298(3):1142-9 - PubMed
    1. Bioorg Med Chem Lett. 2009 Jun 15;19(12):3174-6 - PubMed
    1. J Mol Biol. 2004 Mar 19;337(2):355-65 - PubMed
    1. J Biol Chem. 2001 Apr 6;276(14):11189-98 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources